Novavax (NVAX) Reports Q4 EPS of ($11.28), Guides 2022 Revenue of $4-$5B
Tweet
Share
E-mail
Get Alerts NVAX Hot Sheet
Price: $8.88 +3.74%
EPS Growth %: -164.5%
Financial Fact:
Loss from operations: -63.31M
Today's EPS Names:
CGEH, NAKA, APOG, More
EPS Growth %: -164.5%
Financial Fact:
Loss from operations: -63.31M
Today's EPS Names:
CGEH, NAKA, APOG, More
Join SI Premium – FREE
Novavax (NASDAQ: NVAX) reported Q4 EPS of ($11.28), $10.73 worse than the analyst estimate of ($0.55). Revenue for the quarter came in at $222 million versus the consensus estimate of $442.77 million.
GUIDANCE:
Novavax sees FY2022 revenue of $4-5 million.
For earnings history and earnings-related data on Novavax (NVAX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- onsemi downgraded by TD Cowen after Synaptics deal clouds growth story
- AES stockholders approve $10.7 billion takeover by GIP and EQT
- JPMorgan Starts TIME dotCom Berhad (TDC:MK) at Overweight
Create E-mail Alert Related Categories
Corporate News, Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
